Abstract

Described are implantable devices having reservoirs for the sustained release of therapeutic agents. The devices are configured to be at least partially implanted in an eye and include a retention structure and a penetrable element coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element is positioned in fluid communication with an outlet of the device and a reservoir having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61B 17/00 - Surgical instruments, devices or methods
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61L 27/02 - Inorganic materials
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/178 - Syringes
• A61M 5/31 - Syringes Details
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
• A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
• A61M 39/02 - Access sites

Abstract

Disclosed is an intraocular lens device for treatment of an eye including a shape changing membrane configured to outwardly bow in a region surrounding the optical axis of the eye. The lens device also includes a force translation arm configured to move upon movement of the ciliary structure.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/008 - Methods or devices for eye surgery using laser

Abstract

Described herein are intraocular lenses and methods of implantation. In one aspect, the lens includes a shape changing optical element; a force translation element having a first end region coupled to the optical element and a second end region extending towards a ciliary structure, and an attachment portion coupled to the second end region of the force translation element and configured to contact the ciliary structure. The force translation element is configured to functionally transmit movements of the ciliary structure into a force exerted upon the optical element to effect an accommodating and a disaccommodating change of the optical element.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

An apparatus to treat a patient comprises a container to receive fluid of a device implanted in the eye. The fluid of the device can be analyzed to determine a component of the vitreous humor of the eye.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

Described herein, inter alia, are fluorosilicone polymers; compositions comprising fluorosilicone polymers; and lenses comprising the polymers, and compositions.

IPC Classes  ?

• C08G 77/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon
• G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics

Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. TABLE 1A Therapeutic Agent List Generic Name Brands (Companies) Category Indication Molecular Weight 2-Methoxyestradiol analogs (Paloma Pharmaceuticals) Angiogenesis inhibitors AMD 3-aminothalidomide 13-cis retinoic acid Accutane™ (Roche Pharmaceuticals) A0003 (Aqumen BioPharmaceuticals) A0003 AMD A5b1 integrin inhibitor (Jerini Ophthalmic); (Ophthotech) Inhibitors of a5b1 integrin AMD Abarelix Plenaxis™(Praecis Pharmaceuticals) Anti-Testosterone Agents; Antineoplastic Agents For palliative treatment of advanced prostate cancer. 37731 Abatacept Orencia™(Bristol-Myers Squibb) Antirheumatic Agents For the second line reduction of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients who have 37697 Abciximab ReoPro™; ReoPro™ (Centocor) Anticoagulants; Antiplatelet Agents For treatment of myocardial infarction, adjunct to percutaneous 2oronary intervention, unstable angina 42632 ABT-578 (Abbott Laboratories) Limus Immunophilin Binding Compounds Acetonide Adalimumab Humira™ (Abbott Laboratories) Antirheumatic Agents; Immunomodulatory Agents For treatment of rheumatoid arthritis 25645 Aldesleukin Proleukin™; Proleukin™ (Chiron Corp) Antineoplastic Agents For treatment of adults with metastatic renal cell carcinoma 61118 Alefacept Amevive™ Immunomodulatory Agents; Immunosuppressive Agents For treatment of moderate to severe chronic plaque psoriasis 42632 Alemtuzumab Campath™; Campath™ (ILEX Pharmaceuticals LP); MabCampath™ Antineoplastic Agents For treatment of B-cell chronic lymphocytic leukemia 6614 Alpha-1-proteinase inhibitor Aralast™ (Baxter); Prolastin™ (Talecris Biotherapeutics C formerly Bayer) Enzyme Replacement Agents For treatment of panacinar emphysema 28518 Alteplase Activase™ (Genentech Inc) Thrombolytic Agents For management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli 54732 AMG-1470 Anakinra Kineret™ (Amgen Inc) Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Immunomodulatory Agents For the treatment of adult rheumatoid arthritis. 65403 Anecortave acetate Angiostatin Anistreplase Eminase™ (Wulfing Pharma GmbH) Thrombolytic Agents For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction 54732 Anti-angiogenesis peptides (Eyecopharm) Anti-angiogenesis peptides AMD Anti-angiogenesis antibodies, TRC093, TRC105 (TRACON Pharma) Anti-angiogenesis antibodies AMD Anti-angiogeric bifunctional protein Icon-1™ (Iconic Therapeutics) Anti-angiogeric bifunctional protein, Icon-1 AMD Anti-endothelial growth factor Antihemophilic Factor Advate™; Alphanate™; Bioclate™; Helixate™; Helixate FS™; Hemofil M™; Humate-P™; Coagulants; Thrombotic Agents For the treatment of hemophilia A, von Willebrand diseae and Factor XIII deficiency 70037 Hyate:C™; Koate-HP™; Kogenate™; Kogenate FS™; Monarc-M™; Monoclate-P™; ReFacto™; Xyntha™ Antithymocyte globulin Genzyme); Thymoglobulin™ (SangStat Medical Immunomodulatory Agents For prevention of renal transplant rejection 37173 Anti-hypertensive MC1101 (MacuCLEAR) Anti-hypertensive MC1101 AMD Anti-platelet devired growth factor Anti-VEGF (Neurotech); Avastin™ (NeoVista) Anti-VEGF AMD AP23841 (Ariad) Limus Immunophilin Binding Compounds Aprotinin Trasylol™ Antifibrinolytic Agents For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusio 90569 Arcitumomab CEA-Scan™ Diagnostic Agents; Imaging Agents For imaging colorectal tumors 57561 Asparaginase Elspar™ (Merck & Co. Inc) Antineoplastic Agents For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma 132.118 Axitinib Tyrosine Kinase Inhibitors 386 Basiliximab Simulect™ (Novartis Pharmaceuticals) Immunomodulatory Agents; Immunosuppressive Agents For prophylactic treatment of kidney transplant rejection 61118 Becaplermin Regranex™; Regranex™ (OMJ Pharmaceuticals) Anti-Ulcer Agents; Topical For topical treatment of skin ulcers (from diabetes) 123969 Bevacizumab Avastin™; Avastin™ (Genentech Inc) Antiangiogenesis Agents; Antineoplastic Agents For treatment of metastatic colorectal cancer 27043 Bivalirudin Angiomax™; Angiomax™ (Medicines Co or MDCO); Angiox™ Anticoagulants; Antithrombotic Agents For treatment of heparin-induced thrombocytopenia 70037 Bortezomib Proteosome Inhibitors Bosutinib Tyrosine Kinase Inhibitors 530 Botulinum Toxin Type A BOTOX™(Allegran Inc); BOTOX Cosmetic™ (Allegran Inc); Botox™; Dysport™ Anti-Wrinkle Agents; Antidystonic Agents; Neuromuscular Blocking Agents For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical 23315 Botulinum Toxin Type B Myobloc™ (Solstice Neurosciences); Neurobloc™ (Solstice Neurosciences) Antidystonic Agents For the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. 12902 C5 inhibitor (Jerini Ophthalmic) ; (Ophthotech) Inhibitors of C5 AMD Canstatin Capromab ProstaScint™ (Cytogen Corp) Imaging Agents For diagnosis of prostate cancer and detection of intra-pelvic metastases 84331 Captopril ACE Inhibitors CCI-779 (Wyeth) Limus Immunophilin Binding Compounds Cediranib Tyrosine Kinase Inhibitors 450 Celecoxib Cyclooxygenase Inhibitors Cetrorelix Cetrotide™ Hormone Antagonists; Infertility Agents For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation 78617 Cetuximab Erbitux™; Erbitux™ (ImClone Systems Inc) Antineoplastic Agents For treatment of metastatic colorectal cancer. 42632 Choriogonadotropin alfa Novarel™; Ovidrel™; Pregnyl™; Profasi™ Fertility Agents; Gonadotropins For the treatment of female infertility 78617 Cilary neurotrophic factor (Neurotech) Cilary neurotrophic factor AMD Coagulation Factor IX Benefix™ (Genetics Institute) Coagulants; Thrombotic Agents For treatment of hemophilia (Christmas disease). 267012 Coagulation factor VIIa NovoSeven™ (Novo Nordisk) Coagulants; Thrombotic Agents For treatment of hemorrhagic complications in hemophilia A and B 54732 Colchicines Collagenase Cordase™; Santyl™ (Advance Biofactures Corp); Xiaflextm™ Anti-Ulcer Agents; Topical For treatment of chronic dermal ulcers and severe skin burns 138885 Complement factor H recombinant (Optherion); (Taligen Therapeutics) Complement factor H recombinant AMD Compstatin derivative peptide, POT-4 (Potentia Pharmaceuticals) Complement Factor C3 Inhibitors; Compstatin Derivative Peptides AMD Corticotropin ACTH™; Acethropan™; Acortan™; Acthar™; Exacthin™; H.P. Acthar Gel™; Isactid™; Purified cortrophin gel™; Reacthin™; Solacthyl™; Tubex Diagnostic Agents For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. 33927 Cosyntropin Cortrosyn™; Synacthen depot™ Diagnostic Agents For use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. 33927 Cyclophilins Limus Immunophilin Binding Compounds Cyclosporine Gengraf™ (Abbott labs); Neoral™ (Novartis); Restasis™; Restasis™ (Allergan Inc); Sandimmune™ (Novartis); Sangcya™ Antifungal Agents; Antirheumatic Agents; Dermatologic Agents; Enzyme Inhibitors; Immunomodulatory Agents; Immunosuppressive Agents For treatment of transplant rejection, rheumatoid arthritis, severe psoriasis 32953 Daclizumab Zenapax™ (Hoffmann-La Roche Inc) Immunomodulatory Agents; Immunosuppressive Agents For prevention of renal transplant rejection 61118 Darbepoetin alfa Aranesp™ (Amgen Inc.) Antianemic Agents For the treatment of anemia (from renal transplants or certain HIV treatment) 55066 Dasatinib Tyrosine Kinase Inhibitors 488 Defibrotide Dasovas™; Noravid™; Prociclide™ Antithrombotic Agents Defibrotide is used to treat or prevent a failure of normal blood flow (occlusive venous disease, OVD) in the liver of patients who have had bone marrow transplants or received certain drugs such as oral estrogens, mercaptopurine, and many others. 36512 Denileukin diftitox Ontak™ Antineoplastic Agents For treatment of cutaneous T-cell lymphoma 61118 Desmopressin Adiuretin™; Concentraid™; Stimate™ Antidiuretic Agents; Hemostatics; Renal Agents For the management of primary nocturnal enuresis and indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pitu 46800 Dexamethasone Ozurdex™ (Allergan) Glucocorticoid DME, inflammation, macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) 392 Diclofenac Cyclooxygenase Inhibitors Dithiocarbamate NFκB Inhibitor Dornase Alfa Dilor™; Dilor-400™; Lufyllin™; Lufyllin-400™; Neothylline™; Pulmozyme™ (Genentech Inc) Enzyme Replacement Agents For the treatment of cystic fibrosis. 7656 (double strand) Drotrecogin alfa Xigris™; Xigris™ (Eli Lilly & Co) Antisepsis Agents For treatment of severe sepsis 267012 Eculizumab Soliris™; Soliris™ (Alexion Pharmaceuticals) For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. 188333 Efalizumab Raptiva™; Raptiva™ (Genentech Inc) Immunomodulatory Agents; Immunosuppressive Agents For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. 128771 Endostatin Enfuvirtide Fuzeon™; Fuzeon™ (Roche Pharmaceuticals) Anti-HIV Agents; HIV Fusion Inhibitors For treatment of HIV AIDS 16768 Epoetin alfa Epogen™ (Amgen Inc.); Epogin™ (Chugai); Epomax™ (Elanex); Eprex™ (Janssen-Cilag. Ortho Biologics LLC); NeoRecormon™ (Roche); Procrit™ (Ortho Biotech); Recormon™ (Roche) Antianemic Agents For treatment of anemia (from renal transplants or certain HIV treatment) 55066 Eptifibatide Integrilin™; Integrilin™ (Millennium Pharm) Anticoagulants; Antiplatelet Agents; Platelet For treatment of myocardial infarction and acute coronary syndrome. 7128 Aggregation Inhibitors Erlotinib Tyrosine Kinase Inhibitors 393 Etanercept Enbrel™; Enbrel™ (Immunex Corp) Antirheumatic Agents; Immunomodulatory Agents For treatment of severe adult and 9ocalizi rheumatoid arthritis 25645 Everolimus Limus Immunophilin Binding Compounds Exenatide Byetta™; Byetta™ (Amylin/Eli Lilly) Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control. 53060 Felypressin Felipresina™ [INN-Spanish]; Felipressina™ [DCIT]; Felypressin™ [USAN:BAN:INN]; Felypressine™ [INN-French]; Felypressinum™ [INN-Latin]; Octapressin™ Renal Agents; Vasoconstrictor Agents For use as an alternative to adrenaline as a 9ocalizing agent, provided that local ischaemia is not essential. 46800 Fenretinide (Sirion Therapeutics) Binding Protein Antagonist for Oral Vitamin A AMD Filgrastim Neupogen™ (Amgen Inc.) Anti-Infective Agents; Antineutropenic Agents; Immunomodulatory Agents Increases leukocyte production, for treatment in non-myeloid cancer,neutropenia and bone marrow transplant 28518 FK605-binding proteins, FKBPs Limus Immunophilin Binding Compounds Fluocinolone Acetonide Retisert™ (Bausch & Lomb); Iluvien™ (Alimera Sciences, Inc.) Glucocorticoid Retinal inflammation, diabetic macular edema 453 Follitropin beta Follistim™ (Organon); Gonal F™; Gonal-F™ Fertility Agents For treatment of female infertility 78296 Fumagillin Galsulfase Naglazyme™; Naglazyme™ (BioMarin Pharmaceuticals) Enzyme Replacement Agents For the treatment of adults and children with Mucopolysaccharidosis VI. 47047 Gefitinib Tyrosine Kinase Inhibitors 447 Gemtuzumab ozogamicin Mylotarg™; Mylotarg™ (Wyeth) Antineoplastic Agents For treatment of acute myeloid leukemia 39826 Glatiramer Acetate Copaxone™ Adjuvants, Immunologic; Immunosuppressive Agents For reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis. 29914 Glucagon recombinant GlucaGen™ (Novo Nordisk); Glucagon™ (Eli Lilly) Antihypoglycemic Agents For treatment of severe hypoglycemia, also used in gastrointestinal imaging 54009 Goserelin Zoladex™ Antineoplastic Agents; Antineoplastic Agents, Hormonal Breast cancer; Prostate carcinoma; Endometriosis 78617 Human Serum Albumin Albutein™ (Alpha Therapeutic Corp) Serum substitutes For treatment of severe blood loss, hypervolemia, hypoproteinemia 39000 Hyaluronidase Vitragan™; Vitrase™; Vitrase™ (Ista Pharma) Anesthetic Adjuvants; Permeabilizing Agents For increase of absorption and distribution of other injected drugs and for rehydration 69367 Ibritumomab Zevalin™ (IDEC Pharmaceuticals) Antineoplastic Agents For treatment of non-Hodgkin’s lymphoma 33078 Idursulfase Elaprase™ (Shire Pharmaceuticals) Enzyme Replacement Agents For the treatment of Hunter syndrome in adults and children ages 5 and older. 47047 Imatinib Tyrosine Kinase Inhibitors 494 Immune globulin Civacir™; Flebogamma™ (Instituto Grifols SA); Gamunex™ (Talecris Biotherapeutics) Anti-Infectives; Immunomodulatory Agents For treatment of immunodeficiencies, thrombocytopenic purpura, Kawasaki disease, gammablobulinemia, leukemia, bone transplant 42632 Infliximab Remicade™ (Centocor Inc) Immunomodulatory Agents; Immunosuppressive Agents For treatment of Crohn’s disease, psoriasis, rheumatoid 11cuminate and ankylosing spondylitis 25645 Insulin Glargine recombinant Lantus™ Hypoglycemic Agents For treatment of diabetes (type I and II) 156308 Insulin Lyspro recombinant Humalog™ (Eli Lily); Insulin Lispro (Eli Lily) Hypoglycemic Agents For treatment of diabetes (type I and II) 154795 Insulin recombinant Novolin R™ (Novo Nordisk) Hypoglycemic Agents For treatment of diabetes (type I and II) 156308 Insulin, porcine Iletin II™ Hypoglycemic Agents For the treatment of diabetes (type I and II) 156308 Interferon Interferon Alfa-2a, Recombinant Roferon A™ (Hoffmann-La Roche Inc); Veldona™ (Amarillo Biosciences) Antineoplastic Agents; Antiviral Agents For treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi’s sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection. 57759 Interferon Alfa-2b, Recombinant Intron A™ (Schering Corp) Antineoplastic Agents; Antiviral Agents; Immunomodulatory Agents For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi’s sarcoma. 57759 Interferon alfacon-1 Advaferon™; Infergen™ (InterMune Inc) Antineoplastic Agents; Antiviral Agents; Immunomodulatory Agents For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi’s sarcoma 57759 Interferon alfa-n1 Wellferon™ (GlaxoSmithKline) Antiviral Agents; Immunomodulatory Agents For treatment of venereal or genital warts caused by the Human Papiloma Virus 57759 Interferon alfa-n3 Alferon™ (Interferon Sciences Inc.); Alferon LDO™; Alferon N Injection™ Antineoplastic Agents; Antiviral Agents; Immunomodulatory Agents For the intralesional treatment of refractory or recurring external condylomata 12cuminate. 57759 Interferon beta-1b Betaseron™ (Chiron Corp) Antiviral Agents; Immunomodulatory Agents For treatment of relapsing/remitting multiple sclerosis 57759 Interferon gamma-1b Actimmune™; Actimmune™ (InterMune Inc) Antiviral Agents; Immunomodulatory Agents For treatment of Chronic granulomatous disease, Osteopetrosis 37835 Lapatinib Tyrosine Kinase Inhibitors 581 Lepirudin Refludan™ Anticoagulants; Antithrombotic Agents; Fibrinolytic Agents For the treatment of heparin-induced thrombocytopenia 70037 Lestaurtinib Tyrosine Kinase Inhibitors 439 Leuprolide Eligard™ (Atrix Labs/QLT Inc) Anti-Estrogen Agents; Antineoplastic Agents For treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty 37731 Lutropin alfa Luveris™ (Serono) Fertility Agents For treatment of female infertility 78617 Mecasermin Increlex™; Increlex™ (Tercica); Iplex For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypoth 154795 Menotropins Repronex™ Fertility Agents For treatment of female infertility 78617 mTOR inhibitors Muromonab Orthoclone OKT3™ (Ortho Biotech) Immunomodulatory Agents; For treatment of organ transplant recipients, 23148 Immunosuppressive Agents prevention of organ rejection Natalizumab Tysabri™ Immunomodulatory Agents For treatment of multiple sclerosis. 115334 Nepafenac Cyclooxygenase Inhibitors Nesiritide Natrecor™ Cardiac drugs For the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. 118921 Nilotinib Tyrosine Kinase Inhibitors 530 NS398 Cyclooxygenase Inhibitors Octreotide Atrigel™; Longastatin™ ; Sandostatin™; Sandostatin LAR™; Sandostatin LAR™ (Novartis) Anabolic Agents; Antineoplastic Agents, Hormonal; Gastrointestinal Agents; Hormone Replacement Agents For treatment of acromegaly and reduction of side effects from cancer chemotherapy 42687 Omalizumab Xolair™ (Genentech Inc) Anti-Asthmatic Agents; Immunomodulatory Agents For treatment of asthma caused by allergies 29596 Oprelvekin Neumega™; Neumega™ (Genetics Institute Inc) Coagulants; Thrombotics Increases reduced platelet levels due to chemotherapy 45223 OspA lipoprotein LYMErix™ (SmithKline Beecham) Vaccines For prophylactic treatment of Lyme Disease 95348 OT-551 (Othera) Anti-oxidant eyedrop AMD Oxytocin Oxytocin™ (BAM Biotech); Pitocin™ (Parke-Davis); Syntocinon™ (Sandoz) Anti-tocolytic Agents; Labor Induction Agents; Oxytocics To assist in labor, elective labor induction, uterine contraction induction 12722 Palifermin Kepivance™ (Amgen Inc) Antimucositis Agents For treatment of mucositis (mouth sores) 138885 Palivizumab Synagis™ Antiviral Agents For treatment of respiratory diseases casued by respiratory syncytial virus 63689 Panitumumab Vectibix™; Vectibix™ (Amgen) Antineoplastic Agents For the treatment of EGFR-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens. 134279 PDGF inhibitor (Jerini Ophthalmic); (Ophthotech) Inhibitors of PDGF AMD PEDF (pigment epithelium derived factor) Pegademase bovine Adagen™ (Enzon Inc.) Enzyme Replacement Agents For treatment of adenosine deaminase deficiency 36512 Pegaptanib Macugen™ Oligonucleotide For the treatment of neovascular (wet) age-related macular degeneration. 103121 Pegaspargase Oncaspar™ (Enzon Inc) Antineoplastic Agents For treatment of acute lymphoblastic leukemia 132.118 Pegfilgrastim Neulasta™ (Amgen Inc.) Anti-Infective Agents; Antineutropenic Agents; Immunomodulatory Agents Increases leukocyte production, for treatment in non-myeloid cancer, neutropenia and bone marrow transplant 28518 Peginterferon alfa-2a Pegasys™ (Hoffman-La Roche Inc) Antineoplastic Agents; Antiviral Agents; Immunomodulatory Agents For treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi’s sarcoma. 57759 Peginterferon alfa-2b PEG-Intron (Schering Corp); Unitron PEG™ Antineoplastic Agents; Antiviral Agents; Immunomodulatory Agents For the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age. 57759 Pegvisomant Somavert™ (Pfizer Inc) Anabolic Agents; Hormone Replacement Agents For treatment of acromegaly 71500 Pentoxifylline Perindozril ACE Inhibitors Pimecrolimus Limus Immunophilin Binding Compounds PKC (protein kinase C) inhibitors Pramlintide Symlin™; Symlin™ (Amylin Pharmaceuticals) For the mealtime treatment of Type I and Type II diabetes in combination with standard insulin therapy, in patients who have failed to achieve adequate glucose control on insulin monotherapy. ) 16988 Proteosome inhibitors Velcade™ Proteosome inhibitors Pyrrolidine Quinopril ACE Inhibitors Ranibizumab Lucentis™ For the treatment of patients with neovascular (wet) age-related macular degeneration. 27043 Rapamycin (siroliums) (MacuSight) Limus Immunophilin Binding Compounds AMD Rasburicase Elitek™ ; Elitek™ (Sanofi-Synthelabo Inc); Fasturtec™ Antihyperuricemic Agents For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy) 168.11 Reteplase Retavase™ (Centocor); Retavase™ (Roche) Thrombolytic Agents For lysis of acute pulmonary emboli, intracoronary emboli and 54732 management of myocardial infarction Retinal stimulant Neurosolve™ (Vitreoretinal Technologies) Retinal stimulants AMD Retinoid(s) Rituximab MabThera™; Rituxan™ Antineoplastic Agents For treatment of B-cell non-Hodgkins lymphoma (CD20 positive) 33078 RNAI (RNA interference of angiogenic factors) Rofecoxib Vioxx™; Ceoxx™; Ceeoxx™ (Merck & Co.) Cyclooxygenase Inhibitors Rosiglitazone Thiazolidinediones Ruboxistaurin Eli Lilly Protein Kinase C (PKC)-b Inhibitor DME, diabetic peripheral retinopathy 469 Salmon Calcitonin Calcimar™; Miacalcin™ (Novartis) Antihypocalcemic Agents; Antiosteporotic Agents; Bone Density Conservation Agents For the treatment of postmenopausal osteoporosis 57304 Sargramostim Immunex™; Leucomax™ (Novartis); Leukine™; Leukine™ (Berlex Laboratories Inc) Anti-Infective Agents; Antineoplastic Agents; Immunomodulatory Agents For the treatment of cancer and bone marrow transplant 46207 SDZ-RAD Limus Immunophilin Binding Compounds Secretin SecreFlo™; Secremax™, SecreFlo™ (Repligen Corp) Diagnostic Agents For diagnosis of pancreatic exocrine dysfunction and gastrinoma 50207 Selective inhibitor of the factor 3 complement cascade Selective inhibitor of the factor 5 complement cascade Semaxanib Tyrosine Kinase Inhibitors 238 Sermorelin Geref™ (Serono Pharma) Anabolic Agents; Hormone Replacement Agents For the treatment of dwarfism, prevention of HIV-induced weight loss 47402 Serum albumin iodinated Megatope™ (IsoTex Diagnostics) Imaging Agents For determination of total blood and plasma volumes 39000 Siroliums reformulation (rapamycin) (MacuSight) Limus Immunophilin Binding Compounds AMD siRNAi molecule synthetic, FTP-801i-14 (Quark Pharmaceuticals) siRNAi molecule synthetic AMD Somatropin recombinant BioTropin™ (Biotech General); Genotropin™ (Pfizer); Humatrope™ (Eli Lilly); Norditropin™ (Novo Nordisk); Nutropin™ (Genentech Inc.); NutropinAQ™ (Genentech Inc.); Protropin™ (Genentech Inc.); Saizen™ (Serono SA); Serostim™; Serostim™ (Serono SA); Tev-Tropin™ (GATE) Anabolic Agents; Hormone Replacement Agents For treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss 71500 Squalamine Streptokinase Streptase™ (Aventis Behringer GmbH) Thrombolytic Agents For the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or embolism and occlusion of arteriovenous cannulae 90569 Sunitinib Tyrosine Kinase Inhibitors 398 Tacrolimus Limus Immunophilin Binding Compounds Tenecteplase TNKase™ (Genentech Inc) Thrombolytic Agents For treatment of myocardial infarction and lysis of intracoronary emboli 54732 Teriparatide Apthela™; Forsteo™; Forteo™; Fortessa™; Opthia™; Optia™; Optiah™; Zalectra™; Zelletra™ Bone Density Conservation Agents For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. 66361 Tetrathiomolybdate Thyrotropin Alfa Thyrogen™ (Genzyme Inc) Diagnostic Agents For detection of residueal or recurrent thyroid cancer 86831 Tie-1 and Tie-2 kinase inhibitors Toceranib Tyrosine Kinase Inhibitors 396 Tositumomab Bexxar™ (Corixa Corp) Antineoplastic Agents For treatment of non-Hodgkin’s lymphoma (CD20 positive, follicular) 33078 TPN 470 analogue Trastuzumab Herceptin™ (Genentech) Antineoplastic Agents For treatment of HER2-positive pulmonary breast cancer 137912 Triamcinolone acetonide Triesence™ Glucocorticoid DME, For treatment of inflammation of the retina 435 Troglitazone Thiazolidinediones Tumistatin Urofollitropin Fertinex™ (Serono S.A.) Fertility Agents For treatment of female infertility 78296 Urokinase Abbokinase™; Abbokinase™ (Abbott Laboratories) Thrombolytic Agents For the treatment of 19ulmonary embolism, coronary artery thrombosis and IV catheter clearance 90569 Vandetanib Tyrosine Kinase Inhibitors 475 Vasopressin Pitressin™; Pressyn™ Antidiuretics; Oxytocics; Vasoconstrictor Agents For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding 46800 Vatalanib Tyrosine Kinase Inhibitors 347 VEGF receptor kinase inhibitor VEGF Trap Aflibercept™ (Regneron Pharmaceuticals, Bayer HealthCare AG) Genetically Engineered Antibodies DME, cancer, retinal vein occlusion, choroidal neovascularization, delay wound healing, cancer treatment 96600 Visual Cycle Modulator ACU-4229 (Acucela) Visual Cycle Modulator AMD Vitamin(s) Vitronectin receptor antagonists Volociximabe Monoclonal antibody

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/02 - Ophthalmic agents
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

An accommodating intraocular lens device for treatment of an eye having a lens body; internal support; stabilization system; and force translation arm. The lens body includes an accommodating membrane, an annular element, a static element, and a fixed volume of optical fluid filling a sealed chamber of the lens body. The annular element coupled to the perimeter of the accommodating membrane has a shape deformation membrane configured to undergo displacement relative to the perimeter region. The sealed chamber is formed by inner surfaces of the accommodating membrane, shape deformation membrane, and static element. The force translation arm has a first end operatively coupled to the shape deformation membrane and a free end available and configured to engage a ciliary structure of the eye. The force translation arm is moveable relative to the lens body to cause inward movement of the shape deformation membrane. Related methods, devices, and systems are provided.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

An implantable device having a reservoir for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and include a retention structure and a penetrable element coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element is positioned in fluid communication with an outlet of the device and a reservoir having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Abstract

Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 39/02 - Access sites

Abstract

A filling apparatus for filling a lens device with a volume of optical liquid including a dispensing system, a venting system having a vacuum pump and a vacuum chamber, a measurement system, and a lens device holding system. The dispensing system includes a source of optical liquid, a positive displacement pump, and a filling needle having a lumen in fluid communication with the source of optical liquid. The filling needle is configured to penetrate an injection zone of the lens device for filling an internal chamber of the lens device. The measurement system is configured to measure a lens zone of the lens device. The lens device holding system includes a lens fixture for maintaining a position of the lens device relative to the filling needle and the measurement system. Related systems, devices, and methods are provided.

IPC Classes  ?

• B29D 11/02 - Artificial eyes from organic plastic material
• A61F 2/16 - Intraocular lenses

Abstract

A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/557 - Eicosanoids, e.g. leukotrienes
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 38/00 - Medicinal preparations containing peptides
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin

Abstract

A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

A device for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Abstract

An ocular implant system including an ocular implant sized and shaped to be inserted at least partially into an eye; a carrier member with a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. A guide sleeve removably attached within at least a first region of the central channel of the shell and defining a proximal port into the central channel that is accessible from the proximal end of the shell. An implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve and having a pair of graspers adapted to releasably secure the implant at a distal end of the implant holder. Related devices, systems, and/or methods are described.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/007 - Methods or devices for eye surgery
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Disclosed is an accommodating intraocular lens device for treatment of an eye including a stabilization haptic (120) configured to be positioned within a region of an eye and a lens body having a sealed chamber containing a fixed volume of optical fluid. The lens body includes a shape changing membrane (145) configured to outwardly bow in a region surrounding the optical axis of the eye; a shape deformation membrane configured to undergo displacement relative to the first shape changing membrane; and a static element (150). An inner surface of the shape changing membrane, an inner surface of the shape deformation membrane and an inner surface of the static element collectively form the sealed chamber. The lens device also includes a force translation arm (115) having a first end configured to contact an outer surface of the shape deformation membrane of the lens body and a second end configured to engage a ciliary structure of the eye. The force translation arm is configured to move relative to the lens body upon movement of the ciliary structure.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/008 - Methods or devices for eye surgery using laser

Abstract

Intraocular lenses having an anterior optic with a central, dynamic zone configured to undergo shape change for accommodation that has a differential thickness gradient between a posterior surface and an anterior surface. Related devices and methods are provided.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

Intraocular lenses having an anterior optic with a central, dynamic zone configured to undergo shape change for accommodation that has a differential thickness gradient between a posterior surface and an anterior surface. Related devices and methods are provided.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

Described herein, inter alia, are fluorosilicone polymers and copolymers; compositions comprising fluorosilicone polymers and copolymers; lenses, such as intraocular lenses, comprising fluorosilicone polymers and copolymers; and processes for making the fluorosilicone polymers and copolymers.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• C08G 77/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon
• C08G 77/24 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen halogen-containing groups
• C08G 77/385 - Polysiloxanes modified by chemical after-treatment containing atoms other than carbon, hydrogen, oxygen or silicon containing halogens

Abstract

Described herein are intraocular lenses and methods of implantation. In one aspect, the lens includes a shape changing optical element; a force translation element having a first end region coupled to the optical element and a second end region extending towards a ciliary structure, and an attachment portion coupled to the second end region of the force translation element and configured to contact the ciliary structure. The force translation element is configured to functionally transmit movements of the ciliary structure into a force exerted upon the optical element to effect an accommodating and a disaccommodating change of the optical element.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

Described are implantable devices having expandable reservoirs for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and includes a retention structure and a penetrable element coupled to and extending within at least a portion of the retention structure. A porous drug release mechanism is positioned in fluid communication with an outlet of the device; and a reservoir having a volume configured to contain one or more therapeutic agents is in fluid communication with the outlet through the porous drug release mechanism. The device is at least partially inserted along an axis of insertion. The reservoir enlarges from an insertion configuration having a first three-dimensional shape to an expanded configuration having a second three-dimensional shape, the second three-dimensional shape being eccentrically positioned relative to the axis of insertion.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Accommodating intraocular (AIOL) assemblies for enabling post implantation in situ manual selective displacement of an AIOL along a human eye's visual axis relative to stationary anchor points. Axial displacement may be over a continuous range or alternatively at discrete axial stopping positions typically from about 100 μm to about 300 μm apart. Novels AIOLs designed to be at least partially folded for facilitating insertion into a human eye through a relatively small incision.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

The present invention pertains to accommodating intraocular lens (AIOL) assemblies including a haptics system for self-anchoring implantation in a human eye's annular ciliary sulcus for retaining an AIOL at a desired position along the human eye's visual axis, and an accommodation measurement implant (AMI) for determining accommodation and accommodation forces in an experimental set-up including an animal's eye.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61P 27/02 - Ophthalmic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 38/38 - Albumins
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/74 - Synthetic polymeric materials

Abstract

A device for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Abstract

Described herein, inter alia, are fluorosilicone polymers and copolymers; compositions comprising fluorosilicone polymers and copolymers; lenses, such as intraocular lenses, comprising fluorosilicone polymers and copolymers; and processes for making the fluorosilicone polymers and copolymers.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61L 27/14 - Macromolecular materials
• C08G 77/24 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen halogen-containing groups
• C08L 83/08 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen
• G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
• G02B 3/12 - Fluid-filled or evacuated lenses

Abstract

Described herein are intraocular lenses and methods of implantation. In one aspect, the lens includes a shape changing optical element; a force translation element having a first end region coupled to the optical element and a second end region extending towards a ciliary structure, and an attachment portion coupled to the second end region of the force translation element and configured to contact the ciliary structure. The force translation element is configured to functionally transmit movements of the ciliary structure into a force exerted upon the optical element to effect an accommodating and a disaccommodating change of the optical element.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 39/02 - Access sites

Abstract

Described are implantable devices having expandable reservoirs for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and includes a retention structure and a penetrable element coupled to and extending within at least a portion of the retention structure. A porous drug release mechanism is positioned in fluid communication with an outlet of the device; and a reservoir having a volume configured to contain one or more therapeutic agents is in fluid communication with the outlet through the porous drug release mechanism. The device is at least partially inserted along an axis of insertion. The reservoir enlarges from an insertion configuration having a first three-dimensional shape to an expanded configuration having a second three-dimensional shape, the second three-dimensional shape being eccentrically positioned relative to the axis of insertion.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

An apparatus to treat a patient comprises a container to receive fluid of a device implanted in the eye. The fluid of the device can be analyzed to determine a component of the vitreous humor of the eye.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor

Abstract

An ocular implant system including an ocular implant sized and shaped to be inserted at least partially into an eye; a carrier member with a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. A guide sleeve removably attached within at least a first region of the central channel of the shell and defining a proximal port into the central channel that is accessible from the proximal end of the shell. An implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve and having a pair of graspers adapted to releasably secure the implant at a distal end of the implant holder. Related devices, systems, and/or methods are described.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/007 - Methods or devices for eye surgery
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/178 - Syringes
• A61M 39/02 - Access sites
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/31 - Syringes Details
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
• A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion

Abstract

An accommodating intraocular lens device for treatment of an eye having a lens body; internal support; stabilization system; and force translation arm. The lens body includes an accommodating membrane, an annular element, a static element, and a fixed volume of optical fluid filling a sealed chamber of the lens body. The annular element coupled to the perimeter of the accommodating membrane has a shape deformation membrane configured to undergo displacement relative to the perimeter region. The sealed chamber is formed by inner surfaces of the accommodating membrane, shape deformation membrane, and static element. The force translation arm has a first end operatively coupled to the shape deformation membrane and a free end available and configured to engage a ciliary structure of the eye. The force translation arm is moveable relative to the lens body to cause inward movement of the shape deformation membrane. Related methods, devices, and systems are provided.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

Disclosed is an accommodating intraocular lens device for treatment of an eye including a stabilization haptic (120) configured to be positioned within a region of an eye and a lens body having a sealed chamber containing a fixed volume of optical fluid. The lens body includes a shape changing membrane (145) configured to outwardly bow in a region surrounding the optical axis of the eye; a shape deformation membrane configured to undergo displacement relative to the first shape changing membrane; and a static element (150). An inner surface of the shape changing membrane, an inner surface of the shape deformation membrane and an inner surface of the static element collectively form the sealed chamber. The lens device also includes a force translation arm (115) having a first end configured to contact an outer surface of the shape deformation membrane of the lens body and a second end configured to engage a ciliary structure of the eye. The force translation arm is configured to move relative to the lens body upon movement of the ciliary structure.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/008 - Methods or devices for eye surgery using laser

Abstract

Accommodating intraocular (AIOL) assemblies for enabling post implantation in situ manual selective displacement of an AIOL along a human eye's visual axis relative to stationary anchor points. Axial displacement may be over a continuous range or alternatively at discrete axial stopping positions typically from about 100 μm to about 300 μm apart. Novels AIOLs designed to be at least partially folded for facilitating insertion into a human eye through a relatively small incision.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

A device (200) for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen (T70) providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber (250) fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

A device (200) for injecting a therapeutic agent into an ocular implant at least partially implanted in an eye including an injection lumen (270) providing a pathway for injecting the therapeutic agent into the implant; an outlet lumen providing a pathway for pre-existing fluid in the ocular implant to exit the implant; and a collection chamber (250) fluidly coupled to the outlet lumen that provides a first fluid outflow resistance and a second fluid outflow resistance. The first fluid outflow resistance is lower than a first resistance to outflow of the implant. The second fluid outflow resistance is greater than a force imparted onto the implant by intraocular pressure of the eye. Injection of therapeutic agent into the implant via the injection lumen causes the pre-existing fluid to exit the implant and enter the collection chamber via the outlet lumen and causes a second pre-existing fluid to displace from the collection chamber.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

The present disclosure includes compositions of a semi-crystalline or crystalline pharmaceutically active agent dispersed in a polymer matrix, in which the active agent is less degraded and, therefore, has lower level of impurities. The present disclosure further includes a method of reducing or preventing physical and chemical degradation of a semi-crystalline or crystalline active agent pharmaceutically active agent dispersed in a polymer matrix. A method of preparation of the composition is also included in this disclosure.

IPC Classes  ?

• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

An implantable device having a reservoir for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and include a retention structure and a penetrable element coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element is positioned in fluid communication with an outlet of the device and a reservoir having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/557 - Eicosanoids, e.g. leukotrienes
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids

Abstract

Described herein are intraocular lenses and methods of implantation. In one aspect, the lens includes a shape changing optical element; a force translation element having a first end region coupled to the optical element and a second end region extending towards a ciliary structure, and an attachment portion coupled to the second end region of the force translation element and configured to contact the ciliary structure. The force translation element is configured to functionally transmit movements of the ciliary structure into a force exerted upon the optical element to effect an accommodating and a disaccommodating change of the optical element.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

IPC Classes  ?

• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 38/38 - Albumins

Abstract

Described herein is an apparatus to insert an implantable therapeutic device into a patient. The apparatus includes a proximal handle and a distal placement portion coupled to the proximal handle and configured to hold the implantable therapeutic device. The distal placement portion includes a first side having a first engagement structure at a distal end of the first side, the first engagement structure configured to surround at least a first portion of a proximal end region of the implantable therapeutic device. The distal placement portion includes a second, opposite side having a second engagement structure at a distal end of the second side, the second engagement structure configured to surround at least a second, opposite portion of the proximal end region of the implantable therapeutic device.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61F 9/007 - Methods or devices for eye surgery
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

An injector apparatus comprises an elongate structure having one or more openings positionable near a penetrable barrier of an implantable device so as to receive fluid of the implantable device. The apparatus comprises a needle and a sheath extending over at least a portion of the needle. The elongate structure may comprise a distal tip to penetrate tissue and the penetrable barrier, and a distal opening near the tip to release therapeutic fluid into the implantable chamber. In many embodiments the distal tip, the distal opening, and the plurality of openings are separated from a stop that engages a tissue of the patient and limit penetration depth such that the distal opening and the plurality of openings are located along an axis of the implantable device to increase an efficiency of the exchange.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 25/00 - CathetersHollow probes
• A61M 39/02 - Access sites
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
• A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
• A61M 39/00 - Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

Accommodating intraocular (AIOL) assemblies for enabling post implantation in situ manual selective displacement of an AIOL along a human eye's visual axis relative to stationary anchor points. Axial displacement may be over a continuous range or alternatively at discrete axial stopping positions typically from about 100 μm to about 300 μm apart. Novels AIOLs designed to be at least partially folded for facilitating insertion into a human eye through a relatively small incision.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61B 17/00 - Surgical instruments, devices or methods
• A61L 27/02 - Inorganic materials
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/178 - Syringes
• A61M 5/31 - Syringes Details
• A61M 39/02 - Access sites
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
• A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion

Abstract

The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor

Abstract

An accommodating intraocular lens device for treatment of an eye having a lens body; internal support; stabilization system; and force translation arm. The lens body includes an accommodating membrane, an annular element, a static element, and a fixed volume of optical fluid filling a sealed chamber of the lens body. The annular element coupled to the perimeter of the accommodating membrane has a shape deformation membrane configured to undergo displacement relative to the perimeter region. The sealed chamber is formed by inner surfaces of the accommodating membrane, shape deformation membrane, and static element. The force translation arm has a first end operatively coupled to the shape deformation membrane and a free end available and configured to engage a ciliary structure of the eye. The force translation arm is moveable relative to the lens body to cause inward movement of the shape deformation membrane. Related methods, devices, and systems are provided.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61F 9/007 - Methods or devices for eye surgery

Abstract

Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

Described are implantable devices having reservoirs for the sustained release of therapeutic agents. The devices are configured to be at least partially implanted in an eye and include a retention structure (105) and a penetrable element (115) coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element (120) is positioned in fluid communication with an outlet of the device and a reservoir (130) having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Described are implantable devices having reservoirs for the sustained release of therapeutic agents. The devices are configured to be at least partially implanted in an eye and include a retention structure (105) and a penetrable element (115) coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element (120) is positioned in fluid communication with an outlet of the device and a reservoir (130) having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61P 27/02 - Ophthalmic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

Disclosed is an accommodating intraocular lens device for treatment of an eye including a stabilization haptic (120) configured to be positioned within a region of an eye and a lens body having a sealed chamber containing a fixed volume of optical fluid. The lens body includes a shape changing membrane (145) configured to outwardly bow in a region surrounding the optical axis of the eye; a shape deformation membrane configured to undergo displacement relative to the first shape changing membrane; and a static element (150). An inner surface of the shape changing membrane, an inner surface of the shape deformation membrane and an inner surface of the static element collectively form the sealed chamber. The lens device also includes a force translation arm (115) having a first end configured to contact an outer surface of the shape deformation membrane of the lens body and a second end configured to engage a ciliary structure of the eye. The force translation arm is configured to move relative to the lens body upon movement of the ciliary structure.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/008 - Methods or devices for eye surgery using laser

Abstract

An ocular implant system including an ocular implant sized and shaped to be inserted at least partially into an eye; a carrier member with a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. A guide sleeve removably attached within at least a first region of the central channel of the shell and defining a proximal port into the central channel that is accessible from the proximal end of the shell. An implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve and having a pair of graspers adapted to releasably secure the implant at a distal end of the implant holder. Related devices, systems, and/or methods are described.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61F 9/007 - Methods or devices for eye surgery

Abstract

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 39/02 - Access sites

Abstract

A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery
• A61K 9/22 - Sustained or differential release type
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61M 5/28 - Syringe ampoules or cartridges, i.e. ampoules or cartridges provided with a needle
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61P 27/02 - Ophthalmic agents

Abstract

The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor

Abstract

A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/557 - Eicosanoids, e.g. leukotrienes
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 38/00 - Medicinal preparations containing peptides
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin

Abstract

The present disclosure includes compositions of a semi-crystalline or crystalline pharmaceutically active agent dispersed in a polymer matrix, in which the active agent is less degraded and, therefore, has lower level of impurities. The present disclosure further includes a method of reducing or preventing physical and chemical degradation of a semi-crystalline or crystalline active agent pharmaceutically active agent dispersed in a polymer matrix. A method of preparation of the composition is also included in this disclosure.

IPC Classes  ?

• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

Described are implantable devices having expandable reservoirs for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and includes a retention structure and a penetrable element coupled to and extending within at least a portion of the retention structure. A porous drug release mechanism is positioned in fluid communication with an outlet of the device; and a reservoir having a volume configured to contain one or more therapeutic agents is in fluid communication with the outlet through the porous drug release mechanism. The device is at least partially inserted along an axis of insertion. The reservoir enlarges from an insertion configuration having a first three-dimensional shape to an expanded configuration having a second three- dimensional shape, the second three-dimensional shape being eccentrically positioned relative to the axis of insertion.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses
• A61P 27/02 - Ophthalmic agents

Abstract

Described are implantable devices having expandable reservoirs for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and includes a retention structure and a penetrable element coupled to and extending within at least a portion of the retention structure. A porous drug release mechanism is positioned in fluid communication with an outlet of the device; and a reservoir having a volume configured to contain one or more therapeutic agents is in fluid communication with the outlet through the porous drug release mechanism. The device is at least partially inserted along an axis of insertion. The reservoir enlarges from an insertion configuration having a first three-dimensional shape to an expanded configuration having a second three-dimensional shape, the second three-dimensional shape being eccentrically positioned relative to the axis of insertion.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

IPC Classes  ?

• G01N 7/10 - Analysing materials by measuring the pressure or volume of a gas or vapour by allowing diffusion of components through a porous wall and measuring a pressure or volume difference
• G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
• G01N 15/08 - Investigating permeability, pore volume, or surface area of porous materials
• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 38/38 - Albumins
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/38 - CelluloseDerivatives thereof
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Abstract

The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 47/40 - CyclodextrinsDerivatives thereof

Abstract

An ocular implant system including an ocular implant sized and shaped to be inserted at least partially into an eye; a carrier member with a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. A guide sleeve removably attached within at least a first region of the central channel of the shell and defining a proximal port into the central channel that is accessible from the proximal end of the shell. An implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve and having a pair of graspers adapted to releasably secure the implant at a distal end of the implant holder. Related devices, systems, and/or methods are described.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/007 - Methods or devices for eye surgery

Abstract

An ocular implant system including an ocular implant sized and shaped to be inserted at least partially into an eye; a carrier member with a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell. A guide sleeve removably attached within at least a first region of the central channel of the shell and defining a proximal port into the central channel that is accessible from the proximal end of the shell. An implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve and having a pair of graspers adapted to releasably secure the implant at a distal end of the implant holder. Related devices, systems, and/or methods are described.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

Disclosed is an accommodating intraocular lens device for treatment of an eye including a stabilization haptic (120) configured to be positioned within a region of an eye and a lens body having a sealed chamber containing a fixed volume of optical fluid. The lens body includes a shape changing membrane (145) configured to outwardly bow in a region surrounding the optical axis of the eye; a shape deformation membrane configured to undergo displacement relative to the first shape changing membrane; and a static element (150). An inner surface of the shape changing membrane, an inner surface of the shape deformation membrane and an inner surface of the static element collectively form the sealed chamber. The lens device also includes a force translation arm (115) having a first end configured to contact an outer surface of the shape deformation membrane of the lens body and a second end configured to engage a ciliary structure of the eye. The force translation arm is configured to move relative to the lens body upon movement of the ciliary structure.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/178 - Syringes
• A61M 5/31 - Syringes Details
• A61M 39/02 - Access sites
• A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
• A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion

Abstract

Described are implantable devices (105) and therapeutic agent delivery formulations for the sustained release of therapeutic agents. In one aspect, described is a device to treat an ocular condition of an eye. The device has a proximal region. A tubular body (115) is coupled to the proximal region and has an outer diameter configured to be inserted at least in part into the eye. A reservoir (130) is in fluid communication with the tubular body and has a volume sized to receive an amount of a formulation of a therapeutic agent. One or more outlets (135) are in fluid communication with the reservoir and configured to release therapeutic amounts of the therapeutic agent into the eye for an extended time when the one or more outlets are positioned inside the eye.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61B 17/00 - Surgical instruments, devices or methods
• A61L 27/02 - Inorganic materials
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

The present disclosure is directed to a pharmaceutical delivery device useful for the treatment of ocular diseases and disorders through sustained release of therapeutic doses of a pharmaceutical agent, while increasing or reducing formation and/or accumulation of mucus.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Described herein is an apparatus to insert an implantable therapeutic device into a patient. The apparatus includes a proximal handle (210) and a distal placement portion (220) coupled to the proximal handle and configured to hold the implantable therapeutic device. The distal placement portion includes a first side (222) having a first engagement structure (251) at a distal end of the first side, the first engagement structure configured to surround at least a first portion of a proximal end region of the implantable therapeutic device. The distal placement portion includes a second, opposite side (224) having a second engagement structure (253) at a distal end of the second side, the second engagement structure configured to surround at least a second, opposite portion of the proximal end region of the implantable therapeutic device.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61F 9/007 - Methods or devices for eye surgery
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

An accommodating intraocular lens (AIOL) for implantation in a human eye includes a housing including an anterior member with a leading surface, a posterior member with a trailing surface, a leading shape memory optical element adjacent the anterior member and resiliently elastically deformable between a non-compressed shape in a non-compressed state of the AIOL and a compressed shape in a compressed state of the AIOL, and a trailing shape memory optical element adjacent the posterior member and elastically deformable between a non-compressed shape in the AIOL's non-compressed state and a compressed shape in the AIOL's compressed state for selectively bulging into the leading shape memory optical element on application of a compression force the said longitudinal axis against the trailing surface from a posterior direction for modifying the shape of the leading shape memory optical element with respect to its non-compressed shape in the AIOL's the non-compressed state.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 39/02 - Access sites

Abstract

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing (130) for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure (120) protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier (140) positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure (150) is positioned within a region of the housing away from the access portion opening into a reservoir chamber (160) extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover (110) is coupled to at least an upper surface of the proximal retention structure.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/007 - Methods or devices for eye surgery
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61M 39/02 - Access sites

Abstract

The present invention is directed to compositions of bimatoprost, processes of preparing these compositions, devices comprising these compositions, and methods of lowering intraocular pressure.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha

Abstract

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing (130) for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure (120) protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier (140) positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure (150) is positioned within a region of the housing away from the access portion opening into a reservoir chamber (160) extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover (110) is coupled to at least an upper surface of the proximal retention structure.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61F 9/008 - Methods or devices for eye surgery using laser

Abstract

Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.

IPC Classes  ?

• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 9/08 - Solutions
• A61K 47/40 - CyclodextrinsDerivatives thereof

Abstract

An apparatus to treat a patient comprises a container to receive fluid of a device implanted in the eye. The fluid of the device can be analyzed to determine a component of the vitreous humor of the eye.

IPC Classes  ?

• A61M 35/00 - Devices for applying media, e.g. remedies, on the human body
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

An intraocular lens is adapted for insertion into a capsular bag having a zonular contact region. The intraocular lens comprises a shape changing optical element and an accommodating element comprising at least one force transmitting element and a plurality of spaced apart contacting elements each adapted to contact a portion of the zonular contact region and transmit compressive displacement radially inward at an oblique angle to the optical element and configured to cooperate with at least one of the ciliary muscle of the mammalian eye, the zonules of the mammalian eye and the vitreous pressure in the eye to effect an accommodating shape and a disaccommodating shape change to the optical element.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

Disclosed is an ocular device including a first structure (135) formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure (112) formed of a second, different material having a tubular structure and a lumen (113) through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand

Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• E21B 49/10 - Obtaining fluid samples or testing fluids, in boreholes or wells using side-wall fluid samplers or testers
• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Abstract

Described herein are intraocular lenses and methods of implantation. In one aspect, the lens includes a shape changing optical element; a force translation element having a first end region coupled to the optical element and a second end region extending towards a ciliary structure, and an attachment portion coupled to the second end region of the force translation element and configured to contact the ciliary structure. The force translation element is configured to functionally transmit movements of the ciliary structure into a force exerted upon the optical element to effect an accommodating and a disaccommodating change of the optical element.

IPC Classes  ?

• A61F 2/16 - Intraocular lenses

Abstract

Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 5/178 - Syringes
• A61M 5/31 - Syringes Details
• A61M 39/02 - Access sites

Abstract

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.

IPC Classes  ?

• A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/74 - Synthetic polymeric materials